Drug companies should release data from all trials of licensed drugs, say MPs

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f321 (Published 16 January 2013)
Cite this as: BMJ 2013;346:f321

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Nigel Hawkes
  1. 1London

The drug industry should be obliged to release in a publicly accessible form all the information it possesses about trials of licensed drugs, the House of Commons Health Committee has said in a new report on the functioning of the National Institute for Health and Clinical Excellence (NICE).1

It should be “neither legal nor ethical” to withhold such data, said the committee. It was concerned that failure to observe this simple principle undermined the effectiveness of NICE, because the institute was forced to appraise drugs without having access to all relevant data.

“This situation cannot be allowed to continue,” said Stephen Dorrell MP, the Conservative chairman of the Health Committee. At a press conference in London to launch the report he called for …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL